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Abstract
Background: Although Nepal legalised abortion in 2002, a significant number of women continue to access unsafe
abortions. An estimated 60% of all abortions performed in 2014 were unsafe, with unsafe abortion continuing to be
a leading contributor to maternal mortality. Despite medical abortion access being solely permitted through government
accredited safe abortion services, medical abortion pills are readily available for illegal purchase at pharmacies throughout
the country.
Methods: Utilising an Assets Focused Rapid Participatory Appraisal (AFRPA) research methodology, underpinned by a
health information pyramid conceptual framework, this qualitative exploratory study collected data from in-depth,
open-ended interviews. The study explored the medical abortion and sexual and reproductive health experiences of
ten women who accessed medical abortion through an accredited safe abortion service, and ten women who
accessed unsafe medical abortion through pharmacies.
Results: Thematic content analysis revealed emerging themes relating to decision-making processes in accessing safe
or unsafe medical abortion; knowledge of safe abortion services; and SRH information access and post-abortion
contraceptive counselling. Findings emphasised the interconnectivity of sexual and reproductive health and
rights; reproductive coercion; education; poverty; spousal separation; and women’s personal, social and economic
empowerment.
Conclusions: While barriers to safe abortion services persist, so will the continued demand for medical abortion
provision through pharmacies. Innovated and effective harm reduction implementations combined with access
and information expansion strategies offer the potential to increase access to safe medical abortion while
decreasing adverse health outcomes for women.
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Plain English Summary
Although abortion is legal in Nepal, unsafe abortion is one
of the leading causes of maternal death. Abortions are
only allowed to be provided by trained health profes-
sionals at government approved services. Despite this re-
striction, medical abortion pills can be easily purchased at
pharmacies throughout the country.
To understand the experiences of women who have
had a medical abortion, 20 women were interviewed: ten
who went to a safe abortion clinic and ten women who
purchased medical abortion pills from a pharmacy. The
interviews showed themes relating to why women go to
safe or unsafe places to get a medical abortion; how
women learned where to get the medical abortion pills
from; what health information women were given; and if
they were offered contraception at the time. The find-
ings highlighted that many factors impact a woman’s de-
cision to have a medical abortion, where she will get it
from and if she will use contraception.
While women continue to face barriers to safe abor-
tion services, there will be a demand for pharmacies to
illegally sell medical abortion pills. Strategies are vitally
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needed to reduce the harm women face by purchasing
medical abortion through pharmacies, as well as expand-
ing ways information about safe medical abortion can be
provided.
Background
The World Health Organization (WHO) and Guttmacher
Institute estimate that between 2010 and 2014, 56 million
induced abortions occurred each year worldwide [1]. Of
these abortions, 25 million unsafe abortions (45% of all
abortions) occurred globally every year, with the majority
of unsafe abortions (97%), occurring in developing coun-
tries in Africa, Asia and Latin America [2]. Abortion is
considered safe when it is performed in accordance with
WHO guidelines and standards, performed by a trained
health worker using WHO-recommended methods ap-
propriate to the pregnancy duration [2–5].
Reconceptualization of the framework and methodology
for estimating unsafe abortion has further divided the
WHO classification of unsafe abortion into two categories
of less safe and least safe [5]. In their 2017 study, Ganatra
et al. classified abortions as less safe if only one of two cri-
teria were met: (1) the abortion was performed by a
trained provider, however an outdated or unsafe method
(e.g., sharp curettage) was utilised or (2) a safe method of
abortion (e.g., mifepristone and/or misoprostol) was used,
but was administered without adequate information or
support from a trained provider. Least safe abortions are
classified as abortions provided by untrained individuals
using dangerous methods such as ingestion of caustic
substances, insertion of foreign objects, and the use of
traditional herbal mixtures or tonics [5]. Of the 25 million
unsafe abortions (45% of all abortions) that occurred an-
nually between 2010 and 2014, an estimated 17 million
(31%) were considered less safe, and 8 million (14%) were
least safe [2, 5].
For over four decades, political and social advocates
from Nepal’s medical and public health communities, sup-
ported by women’s rights activists, pushed for the liberal-
isation of Nepal’s restrictive abortion laws, finally resulting
in the legalisation of surgical abortion (manual vacuum as-
piration) in 2002 and the legalisation of medical abortion
(mifepristone and misoprostol) in 2009 [6]. Under the
current law, abortion is permitted up to 12 weeks of gesta-
tional age on the request of the pregnant women, up to 18
weeks of gestational age in the case of rape or incest
and at any gestational age if the pregnancy is detrimen-
tal to the women’s health and life or if there is foetal
impairment [6, 7].
In Nepal, medical abortion (MA) is the most frequently
accessed method of pregnancy termination (79%), followed
by manual vacuum aspiration (17%) and dilation and
evacuation/dilation and curettage (7%) [8]. However, legal-
isation of abortion alone has not been adequate to facilitate
access to safe abortion services for all women, and many
barriers to services remain [9–13]. Of the estimated 323,
100 abortions performed in Nepal during 2014, nearly 60%
(186, 100) were considered unsafe, having been carried out
by untrained or unregistered providers or self-induced [14].
Faced with a number of social and cultural factors
such as a patriarchal society, limited sexual reproductive
health and rights (SRHR) autonomy and knowledge,
geographic isolation as well as abortion stigma, many
Nepali women remain unaware of the legal status of
abortion and have limited or no knowledge of where to
access safe abortion services [12, 15, 16]. In August
2016, the Government of Nepal announced a strategy to
provide free safe abortion services in Government
clinics, in combination with the provision of free family
planning services, to help mitigate financial barriers to
accessing safe abortion services [17–19]. However,
without simultaneously implementing consistent and
comprehensive monitoring and evaluation of services, it
remains unclear if this strategy can genuinely provide
high quality, effective and equitable safe abortion
services to the women of Nepal [11].
The Government of Nepal registered MA brands
(combined regime of mifepristone and misoprostol),
have been available only on prescription through Gov-
ernment accredited safe abortion providers since 2009
[19, 20]. Despite these restrictions, registered and un-
registered brands of MA are readily available for pur-
chase at pharmacies, often referred to as chemists or
medical shops [14]. The porous border between Nepal
and India enables the illegal entry of unregistered MA
brands as well as ayurvedic and traditional medicines
with supposedly abortive properties, many of which are
then sold illegally through pharmacies [20, 21]. Recent
NHDS data shows that 19% of women who had an abor-
tion reported receiving MA pills from a pharmacist [8].
While the Department of Drug Administration and col-
laborations between the Government, I/NGOs and the
private sector have sought to reduce the illegal possession
and sale of MA through pharmacies, it has proven
challenging and to date, has been unsuccessful [11, 20].
Regardless of illegality, women in Nepal will continue to
access MA through pharmacies, and while there is a high
demand, pharmacies will continue to sell the pills [11]. Al-
though it has been 15 years since the legalisation of abor-
tion in Nepal, unsafe abortion remains the third highest
(7%) direct cause of maternal death in Nepal [12].
Efficient and equitable provision of Post-Abortion
Care (PAC) is an essential component for positive health
outcomes for women who access safe abortion services
and for the prevention of future unintended pregnancies
[22–24]. However, in Nepal, women accessing MA
through pharmacies do not systematically receive any
form of PAC including adequate information regarding
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the administration of the drugs, SRH information, post-
abortion family planning counselling or health care re-
ferral [11].
This qualitative, exploratory study aimed to provide a
unique and in-depth analysis of the post-abortion experi-
ences of women who have accessed MA through safe
abortion services and women who have accessed unsafe
MA by illegally obtaining the medication through phar-
macies. This study explores post-abortion contraceptive
counselling, access and use of contraception among
Nepali women who purchased MA through pharmacies
and offers a rich and detailed examination of their experi-
ences and SRHR needs.
Methods
Using an Assets Focused Rapid Participatory Appraisal
(AFRPA) research methodology, underpinned by a health
information pyramid conceptual framework, known as the
Assets Focused Rapid Participatory Assessment Cycle
(AFRPAC), this qualitative exploratory study utilised data
collected from in-depth, open-ended interviews with 20
women from the Sunsari District of Nepal [25–27]. Partici-
pants included ten women who had accessed MA through
a Marie Stopes Center (Clinic Clients), operated by
Sunaulo Parivar Nepal, an implementing partner of Marie
Stopes International Nepal (SPN/MSN) and ten women
who had accessed medical abortion by illegally obtaining
the tablets through pharmacies (Pharmacy Clients).
The methodology used in the study has an emphasis on
assets and ensures that findings are concurrently solution-
and problem-focused, as opposed to the identification of
problems. Drawing on the perspectives of SRHR profes-
sionals and conversations with a cross-section of commu-
nity members enabled the researchers to acquire a greater
understanding of issues impacting women’s and girls’
SRHR within the local and national contexts and helped
inform interview questions. [11, 28]. Complementing the
qualitative findings, an analysis of current Government
and non-Government SRH policy and clinical practices
was concurrently undertaken.
Participants
Inclusion criteria for participation in this study required
women to be 15 to 49 years of age, able to speak and
understand Nepali, able to give informed consent, live
within the Sunsari District and have previously obtained
MA pills for the termination of a pregnancy.
Clinic clients (CC)
Between September 2014 and April 2016 women attend-
ing the Itahari Marie Stopes Centre (MSC) for safe abor-
tion services were informed of the study by clinic staff.
Of those women, one hundred twelve shared their con-
tact details and consented to be telephoned for potential
research participation. Participants were purposively re-
cruited from this sample of potential participants with
46 of these women meeting the inclusion criteria. To
help mitigate recall bias, women who had accessed MA
3 to 6 months prior to data collection were selected.
Contact was attempted with 23 women with a final ten
women participating in the research. CC clients received
the Nepal Government registered brand of MA - Mar-
iprist (a mifepristone and misoprostol combi-pack).
Pharmacy clients (PC)
Between April and May, 2016, Female Community
Health Volunteers (FCHVs) who were working closely
with the MSC utilised their contacts within the study
community to purposively recruit ten women who met
the inclusion criteria. Due to difficulties with participant
recruitment from this hard to reach community-based
populations, MA access prior to data collection for PC
ranged between approximately 3 weeks to 2 years. The
medication PC participants obtained from a pharmacy
for terminating their unwanted pregnancy is referred to
as MA throughout this paper. However, it is impossible
to ascertain whether they received a Nepal registered
brand of MA, an unregistered, but legitimate brand of
MA, counterfeit MA or a type of ayurvedic medicine
with abortive properties in pill form [20].
Data collection
The interviews were conducted between April and May,
2016, by the first and third authors, who are both female.
A research information sheet, detailing the purpose and
process of the study as well as an informed consent form
was provided to all participants for review prior to inter-
views. Participants were encouraged to ask questions re-
lating to their role in the study as well as any component
of the research. After obtaining written or verbal informed
consent, interviews of approximately 1 h in duration were
conducted with the participants in a convenient, private
location. Eighteen women provided written informed con-
sent and two women, who were not literate, provided ver-
bal informed consent. All interviews were conducted in
Nepali as this was the preferred language of the partici-
pants. Throughout the interviews, the third author (fluent
in both Nepali and English) translated interviewee
responses in English to ensure both interviewers were able
to ask questions and had a comprehensive understanding
of the participants’ responses. Reflective field notes were
taken throughout the interviews.
Data analysis
Audio files were translated and transcribed after the in-
terviews by the third author and a professional trans-
criptionist. A thematic analysis of in-depth interview
content utilising NVivo Software was undertaken by the
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first author, with the first three authors reading the
transcripts and discussing data saturation before col-
laboration and refinement of themes [29]. Thematic
analysis enabled the examination of emergent themes
within the data, facilitating the synthesis of overarch-
ing themes, themes and sub-themes [30, 31]. Analysis
of interview content produced five overarching
themes, 12 themes and 59 sub-themes as detailed in
Additional file 1: Thematic Content Analysis of Inter-
view Transcripts (n = 20).
Rigour in qualitative research is assessed within the con-
text of dependability, credibility, confirmability and trans-
ferability, and trustworthiness [32–34]. To enhance the
credibility and overall trustworthiness of this research,
systematic checking, ongoing interpretation of data and an
audit trail ensured information relating to the study design,
methods and analysis were documented to allow for future
replication [35–37]. Pilot testing of guiding questions was
conducted with all authors assisting in the refinement and
finalisation of the questions prior to the interviews.
Ethical considerations
Ethical approval for this study was granted by the Nepal
Health Research Council (NHRC 20/2014) as well as the
Curtin University Human Research Ethics Committee
(HR 17/2014), and informed consent was a prerequisite of
research participation [38]. Ensuring cultural safety
(aligned with beneficence), was of paramount importance,
and it was essential that participants felt their voices were
heard, that they were respected, and that they felt safe
within the context of the research process [28, 38, 39].
Keeping with the ethical principal of non-maleficence, in-
terviews with PC respondents did not focus on the legality
of MA supply through pharmacies so as not to cause dis-
comfort or distress to participants. As well as confirming
respondents had a clear understanding of their role within
the research and the purpose of the research, to ensure the
ethical principles of justice and beneficence were adhered
to, they were also informed of how their participation will
assist the development of tangible SRHR policy and prac-
tice outcomes [28, 38]. To ensure the confidentiality of par-
ticipants, generic titles detailing whether the participant
was a CC or PC, a participant chosen pseudonym and a par-
ticipant’s reported age, have been used throughout this art-
icle [38]. As many participants had to travel to contribute
to the research, all respondents received 500 Nepali Rupees
(NPR) of transport reimbursement as well as a light meal
with refreshments before the interviews. To thank respon-
dents for their time, all received a voucher for a free health
check-up (detailed as a ‘general health check-up and valued
at 150 NPR) and free pregnancy test (for privacy reasons,
detailed as ‘women’s health check-up’ and valued at 100
NPR) at the NGO collaborating with the research. Initial
findings of the research were disseminated at a community
and stakeholder event in July 2016 in the Sunsari District.
Results
Thematic content analysis of the in-depth interviews re-
vealed emerging themes relating to safe abortion service
provision, knowledge of safe abortion services, SRH infor-
mation access, contraception counselling, geographical
isolation, as well as socioeconomic and sociocultural fac-
tors. Research findings highlight the interconnectivity of
SRHR; gender-based violence in the form of reproductive
coercion and son preference; education; poverty; spousal
separation; and women’s personal, social and economic
empowerment. Table 1 details participant demographic
information and Table 2 details participant reproductive
health information.
Abortion decision-making process
Both CC and PC respondents shared their reasons for
obtaining an abortion and the driving forces behind their
decision to terminate their pregnancies. Of the 20
women who accessed MA, 19 were due to unplanned
pregnancies, and one (CC participant) required a ter-
mination as the foetus was no longer viable. Respon-
dents highlighted the interconnectivity of sociocultural
and socioeconomic factors that informed their decision-
making process. Child spacing was a deciding factor for
several participants living within both single and joint
families. Participants emphasised the difficulties faced by
women in their community to maintain expected gender
roles within the home environment, while also striving
for personal and economic empowerment.
“I was pregnant too soon. My husband also did not want
to have (another) baby immediately… We have many
members in our family, women like us have to manage the
house, so it was difficult.” PC IDI 10, Uma, 25 years
It is seen as a women’s duty to be the primary carer of
children in Nepal and, although many joint households
have multiple female family members to support, many
other mothers undertake parenting duties alone. One par-
ticipant shared her experience of being the sole carer of her
children while pregnant and suffering from health
concerns.
“I had very young children. I had continuous vomiting.
I had to be admitted to hospital, and it was difficult
to take care of my children, so I aborted.” PC IDI 8,
Munna, 30 years
Financial implications of an unwanted pregnancy
were highlighted as key motivator in the abortion
decision-making process for many of the respondents.
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One participant shared her experience of financial in-
security when her son was born and the impact this
experience had on her decision to terminate her next
pregnancy.
“I have no money. I already had son. I had to take loans
during his birth… We had to keep him in the intensive
care unit. I had to invest a lot of money, I have taken
loans, so I do not want to give birth again. If I give birth
again, it will cost.” CC IDI 8, Katrina, 20 years
For participants from lower socioeconomic families,
their unexpected pregnancy was a cause of financial
anxiety. Being able to financially provide for children
was a recurring theme throughout the interviews, with
multiple respondents sharing their inability to care for
and educate the children they have if they were to have
another. Several participants expressed the necessity for
their children to have access to schooling that they did
not have, in order for their children to have a happy
and successful life.
“I did not want any more children, I have son and
daughter… We are poor people, we should manage
food for those children. Giving birth is not enough, we
have to care for them, educate them.” PC IDI 4,
Parvati, 30 years
Themes of reproductive coercion were frequently re-
iterated throughout interviews with both CC and PC
participants. One respondent highlighted the sociocul-
tural struggle many women in Nepal face when it
comes to their reproductive autonomy and their ability
to decide if, and when, they wish to fall pregnant.
“My daughters and son are already grown up, but
my husband still thinks I should (continue) to give
birth... I thought that if it will be aborted with
medicine, despite there will be bleeding, I’ll use
that… I did not tell this to my husband.” PC IDI 2,
Reena, 40 years
Within the patriarchal Nepali society, son-preference
is common, and participants frequently commented on
the pressure from husbands and mothers-in-law to con-
ceive sons. Several respondents shared their happiness
with only having daughters. While they did not person-
ally feel they needed to have sons, one participant spoke
of her husband’s concern of isolation they will experi-
ence in later life when their daughters get married and
leave home.
“My husband says: ‘don’t use (contraception) since we
have only daughters’… Such desires will be in males
only, he wants a son. For woman like me, it’s equal…
Even if I don’t have desire (for more children), because
of the force of husband, I need to give birth. Among
four daughters two already got married. Another two
also will go. After they go, only we two will be alone.
Males think that way. I already have a granddaughter,
I don’t want (more children).” PC IDI 1, Sapana, 36
years
While none of the respondents based their personal
abortion decision-making process from having learnt
Table 1 Participant Demographic Information
Clinic Clients
(n = 10)
Pharmacy Clients
(n = 10)
ALL Participants
(n = 20)
Age
20–25 years 3 3 6
26–30 years 4 3 7
31–35 years 1 2 3
36–40 years 2 2 4
Married
Yes 10 10 20
Husband Works Away*
Yes 4 6 10
No 6 4 10
Family Structure+
Single 6 6 12
Joint 4 4 8
Highest Level of Education
No Primary 0 1 1
Some Primary 2 2 4
Some High School 3 5 8
Obtained SLC^ 4 1 5
Obtained
Bachelor’s Degree
1 0 1
Obtained Master’s
Degree
0 1 1
Language/s Spoken at Home
Nepali 7 9 16
Nepali and Maithili 2 1 3
Nepali and Hindi 1 0 1
Religion
Hindu 10 8 18
Kirat Mundhum 0 1 1
Buddhist 0 1 1
* Husband works away from the family home either within Nepal or overseas
+ Single Family comprises of husband, wife and children. Joint Family
comprises of husband, wife and children as well as members of the extended
family (e.g. grandparents, uncles, aunties, nephews, nieces etc.) living in the
one family home
^ School Leaving Certificate obtained on completion of high school
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the sex of the foetus through ultrasound technology,
several participants shared stories relating to sex-
selective abortions within their communities or ex-
tended families.
Table 2 Participant Reproductive Health Information
Clinic Clients
(n = 10)
Pharmacy Clients
(n = 10)
ALL Participants
(n = 20)
MA use prior to interview#
< 3months 0 2 2
3–6 months 10 2 12
6 months – 1 year 0 1 1
1–2 years 0 3 3
2–3 years 0 2 2
Incomplete abortion
after MA use
Yes 1 3 4
No 9 7 16
Contraceptive use
directly prior to MA
Yes 3 1 4
OCPa 1 0 1
Intermittent OCP 1 1 1
Intermittent
Injectableb
1 0 1
No 7 9 16
No- wanted to
conceive*
1 0 1
Contraceptive use
directly after MA
Yes 10 2 12
Condoms 1 0 1
OCP 5 0 5
Injectable (Depobb)
0 1 1
Implantc
(Norplantcc)
4 0 4
IUDd (Copper Tdd) 0 1+ 1
No 0 8 8
Current contraceptive use
Yes 8 3 11
Condoms 1 0 1
Intermittent OCP 2 0 1
OCP 1 0 2
Depo 0 1 1
Norplant 4 1 5
Copper T 0 1 1
No 2 7 9
No - wants to
conceive ^
0 1 1
Previous abortion/s
None 8 9 17
One 1 1 2
Two 1 0 1
Table 2 Participant Reproductive Health Information (Continued)
Clinic Clients
(n = 10)
Pharmacy Clients
(n = 10)
ALL Participants
(n = 20)
Previous miscarriage/s
None 6 10 16
One 4 0 4
Number of deceased children
None 10 8 18
One 0 1 1
Two 0 1 1
Number of living children
One 4 2 6
Two 5 6 11
Three 0 1 1
Four 1 1 2
Child/children sex-mix
Female and Male 3 5 8
Only Female 4 3 7
Only Male 3 2 5
Age when married
Under 18 years 2 2 4
18–20 years 4 5 9
21–23 years 4 0 4
24–26 years 0 1 1
Not Recorded 0 2 2
Age at birth of first child
Under 18 years 1 1 2
18–20 years 3 4 7
21–23 years 4 2 6
24–26 years 2 1 3
Not Recorded 0 2 2
# Approximate timeframe between the participant taking MA and their
in-depth interview
a Oral Contraceptive Pill
b Hormonal contraceptive injection
bb Hormonal contraceptive injection brand
c Hormonal contraceptive implant
cc Hormonal contraceptive implant brand
d Intrauterine Device
dd Non-hormonal intrauterine device
* The total count for participants not using contraception when they fell
pregnant before their subsequent MA includes one participant who was not
using contraception as she wanted to become pregnant at that time
+ Contraceptive method was not obtained through a pharmacy. Method was
inserted at an SRH Clinic shortly after taking MA
^ The total count for participants currently not using contraception includes
one participant who is not currently using contraception as they want to
become pregnant
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Medical abortion access and uptake: safe abortion
services vs pharmacies
Clinic clients
CC participants frequently stated that advice from
friends and family members played a determining factor
in their decision to access MA through a safe abortion
provider.
“My friend knew about the clinic (MSC). I shared my
problem with her, so she suggested that I go there.” CC
IDI 10, Pratima, 25 years
One CC participant shared that advice from a health
care professional helped her decision making regarding
where to access MA.
“I initially thought about taking medicine from local
medical store but there is a doctor living in our home,
he explained to me that it is not safe to take medicine
this way and suggested I go here (MSC).” CC IDI 5,
Geeta, 28 years
Fear of negative health outcomes from accessing MA
through a pharmacy played a key role in the decision-
making process for several CC participants. This fear
was often the result of learning of others’ negative expe-
riences with pharmacy-supplied MA. Concerns of inad-
equate medical support and referral mechanisms (should
they encounter complications) at pharmacies was reiter-
ated by respondents as key factors in their decision to
attend a safe abortion service.
“First, I did not know about the clinic (MSC). My friends
took medicine (MA) from a pharmacy. For one of my
friends it worked, and for my other friend it did not.
When it was not completely aborted, the same pharmacy
where she purchased the medicine (MA) suggested her to
go to (MSC)… It’s not good practice to go to the pharmacy
for such medicine (MA)... After we give them money the
pharmacy people will give us medicine. Whether it will
be completely aborted or not will be at our own risk.” CC
IDI 10, Pratima, 25 years
Concerns regarding the perceived dangers of inducing
an abortion as well as the medical competency of those
administering MA also played into the decision-making
process for several participants to attend a safe abortion
service for their abortion.
“If the service is taken in a good place after
consulting with an expert in this area, it is safer…
We have heard many people saying somebody took
medicine for abortion and is dead because of it or
is having heavy bleeding now… Does that pharmacy
person have enough idea about the medication to
use, current month of pregnancy? No. So it is
nowhere comparable with the consultation in
hospitals or clinics with experts.” CC IDI 4, Roghini,
32 years
Previous experience of accessing MA through a phar-
macy and having an incomplete abortion was also stated
as being a driving force behind one CC participant at-
tending the MSC for her second abortion.
“(For my) first abortion some of my friends said that
they used medicine from pharmacy for abortion, so
they told me: ‘why you will go to hospital, go in the
pharmacy and take it’… They (pharmacy) did not tell
(me) anything about family planning. They just gave
medicine for abortion… When I took medicine, it was
not aborted completely, so I asked them ‘what to do?’
They suggested I go here (MSC).” CC IDI 8, Katrina,
20 years
The participant goes on to explain that her positive ex-
perience at the MSC for her previous incomplete abor-
tion affected her decision making when she had a
second unplanned pregnancy.
“It is far (to travel) but here the service is good. They
provide proper counselling which I cannot find in
pharmacy. Whether here (MSC) or there (pharmacy), I
have to pay, so I’ll come here.” CC IDI 8, Katrina, 20
years
Nine CC respondents attended the MSC to obtain
their MA in the first instance, and one CC participant
attended the MSC for MA due to an incomplete abor-
tion after taking pharmacy provided MA.
Pharmacy clients
Similar to the CC participants, advice from people within
the community regarding MA access was a considerable
influence on PC respondents’ abortion seeking behaviour.
One PC participant shared that a FCHV informed her she
could purchase MA through a pharmacy. Another PC re-
spondent was told of the ability to access MA through a
pharmacy by a member of the pharmacy staff.
“While buying the pregnancy test kit (at the
pharmacy), I came to know (through information
provided by a staff member) that I can buy that
medicine (MA) there.” PC IDI 8, Munna, 30 years
Positive experiences of friends, family and neighbours
in accessing MA through pharmacies was repeatedly
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stated as a deciding factor for PC participants choosing
to purchase MA through a pharmacy.
“I felt that will be easier. I had heard from others that
they had taken (MA) and it worked well, so I thought
it will be effective.” PC IDI 8, Munna, 30 years
Lack of nearby safe abortion services was highlighted
by several PC participants as the reason they decided to
access MA through a local pharmacy, with one partici-
pant highlighting the fear and worry associated with not
being able to access SRH services.
“I was alone that time, in a remote place. I did not
have friends to take me to the hospital… I had a
friend (working) in pharmacy so I got (MA) through
them… If I have another unplanned pregnancy maybe
I’ll go to a place with more facilities but if I am in a
remote place, I will again have to go to a pharmacy.”
PC IDI 9, Bipana, 31 years
Five of the ten PC participants did not physically pur-
chase the MA from the pharmacy themselves. Instead,
their husbands (three respondents), a female neighbour
(one respondent) and a female friend who works at a
pharmacy (one respondent) purchased the pills and
relayed information to the women.
“I did not know that we could buy those (MA) in
government hospitals, I knew that it can be found in
medicals (pharmacies)… I requested one sister (female
friend) to bring… she works in that pharmacy.” PC
IDI 9, Bipana, 31 years
Medical abortion experience: safe abortion services vs
pharmacies
CC and PC participants shared their experiences of
obtaining MA and their thoughts and emotions towards
the process. Universally, CC participants reported feeling
supported and informed at the time of their clinic ap-
pointment and while several respondents spoke of feeling
scared, said MSC clinic staff were able to reassure them.
Fear of complications was also reported by PC partici-
pants who generally reported that their fear subsided only
when the abortion was complete.
“I was worried what problems might arise. I was also
scared whether it will be completely aborted or not. I
had heard of some women’s death due to
complications.” PC IDI 9, Bipana, 31 years
In contrast, one PC participant shared how support
from her husband and the pharmacy worker providing the
MA (combined with information provided to her husband
by the pharmacy worker), reassured her that her fear of
post-abortion complications was unwarranted.
“I was scared of taking that medicine (MA). He
(husband) gave me consolation not to be scared (and
told me the) pharmacy people said that it won’t be
that bad.” PC IDI 5, Sita, 25 years
While all CC participants said they would access a safe
abortion services again should they have a future un-
planned pregnancy they wished to terminate, PC partici-
pants responses varied regarding future MA access.
While most PC participants noted they would attend a
safe abortion service, one participant shared that due to
limited access to safe abortion services she would again
access MA through a pharmacy, and one PC participant
shared she would purchase MA through a pharmacy
again due to her positive previous experience.
If in case (of another unplanned pregnancy), maybe I’ll
go to the same place (pharmacy) because it worked
well for me. PC IDI 8, Munna, 30 years
Three PC participants had incomplete abortions after
taking pharmacy provided MA requiring access to medical
facilities. One PC participant shared her experience of tak-
ing multiple doses of MA before going to a health facility.
It (MA) did not work. I thought it might take time. I
told the person who brought it (female friend) and
they said that it will be aborted after 2-3 days. But it
was not aborted. So that person gave me another
medicine. It was not aborted even with next dose of
medicine… I thought it will be easily aborted but it
did not happen. PC IDI 4, Parvati, 30 years
Several PC respondents highlighted the lack of medical
referral information in the case of post-abortion compli-
cations. Concerns regarding the saftey and effectiveness
of pharmacy provided MA were raised, as was the med-
ical competency of those providing it.
“They (pharmacy workers) should not do (administer
MA) according to guess… There should be trained health
worker working there. Some women’s life might be at
risk… due to such medicines.” PC IDI 2, Reena, 40 years
Post-abortion contraception and SRH information access
and uptake: safe abortion services vs pharmacies
Clinic clients
All CC respondents reported receiving SRH information
and contraceptive counselling during their appointment
Rogers et al. Reproductive Health          (2019) 16:105 Page 8 of 15
at the MSC (such as MA administration, what to expect
from taking MA and possible side-effects, post-abortion
follow up, contraceptive use education, and fertility de-
sire discussions) with many displaying detailed recall of
SRH information provided during their appointment.
Several participants expressed the empowerment they
now feel regarding their sexual and reproductive health.
“(At my appointment) I became more knowledgeable
about reproductive health. I am able to make self-
decisions now. I can plan my family accordingly…
They (MSC staff ) gave detailed counselling… and in-
formation about contraceptives.” CC IDI 5, Geeta, 28
years
Several participants highlighted the impact post-
abortion family planning counselling had on relieving
their concerns around contraceptive use such as side-
effects and fear of future unplanned pregnancies.
“There were many things I did not know before which I
learnt through this information… I don’t have to be
scared (of unplanned pregnancy) while in sexual
relation after the use of Norplant (Implant).” CC IDI
1, Sabitri, 36 years
Of the ten CC participants, four took up LARC (long-
acting reversible contraception) and six accepted short-
term modern contraceptive methods post-MA. Four had
Implants inserted immediately after taking the first MA
tablet, and all reported continuing the method at the
time of their interview. One CC participant accessed
condoms after their MA and reported continuing to use
this method. Five CC participants accepted OCP at the
time of their MA, with one reporting continuous current
use, two intermittent use and two currently not using
any form of contraception.
Pharmacy clients
Although women in the CC sample expressed relatively
similar experiences relating to SRH information and
contraceptive counselling provided by clinic staff during
their appointments, the PC participants who purchased
the MA themselves shared varied accounts of SRH infor-
mation provision. Several respondents reported they re-
ceived no SRH information other than when to take the
MA tablets, which at the time, caused them concern.
He asked me why I wanted to use medicine. I
answered him the reason that my child was small, so
he gave the medicine. He did not give me any other
information… He just told me that it will work for
some persons and for some it will not… I think that I
should have gotten more information… Like the side
effects of using that medicine.” PC IDI 3, Sita, 28
years
In contrast, other PC respondents reported being pro-
vided with SRH information at the time they purchased
the MA such as MA administration, what to expect
from taking MA and possible side-effects, and what to
do if the abortion is incomplete (e.g., return to the phar-
macy, go to a health clinic or hospital or call the phar-
macy for support). However, only two participants
discussed post-abortion contraceptive use with the phar-
macy staff providing their MA.
“They gave information on how to take the medicine…
and side effects… They said that this medicine works
for some people and for some people it won’t be
completely aborted so in such case should go to
hospital… Because of that (information) I have
knowledge now. They suggested I use Depo
(Injectable)… so I used Depo but it did not react well
with me...now I use Norplant (Implant).” PC IDI 6,
Bharati, 25 years
One PC client shared her experience of accessing MA
through a pharmacy with her husband and highlighted
the necessity for effective, culturally appropriate contra-
ceptive counselling. The couple received information on
MA administration, what to expect and what to do
should complications arise as well as information about
contraception. However, while the respondent felt the
information on MA was useful, she expressed distress
regarding the MA provider’s reaction to her not wanting
to use post-abortion contraception.
“They (pharmacy staff ) informed us (about MA)…
They told us (about contraception) and showed us the
different methods. I already had used them and they
(had) caused problems so we replied that we would
discuss the matter… They yelled at us ‘why are you
are not using contraceptives and are doing abortion?’
They (pharmacy staff ) were angry with us for not
using contraception.” PC IDI 7, Kalpana, 35 years
While other PC respondents stated they would have
like to have received advice on post-abortion contracep-
tion at the time of their MA and indeed, post-abortion
contraception information should have been provided to
them, two PC participants stated they did not expect to
receive this type of information from a pharmacy
worker. Similar to the women who purchased the MA
themselves, SRH information access varied in content
for participants who did not purchase the MA. Several
women reported only being told when to take the pills
and to expect heavy bleeding, while other participants
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recollected more detailed SRH information provision
and support from pharmacy workers.
Only one of the ten PC participants reported accessing
a pharmacy provided method of contraception post-MA.
This PC participant accessed pharmacy provided inject-
ables, reporting they later changed to an Implant
(inserted at a health clinic). One PC respondent had an
intrauterine device (IUD) inserted at a health clinic
shortly after her MA and was still using this contracep-
tive method. Eight PC respondents reported no contra-
ception use post-MA.
Both CC and PC participants shared their post-
abortion contraceptive decision-making process. Over-
whelmingly, PC participants reported similar reasons for
not using a modern method of contraception post-
abortion, the recurring themes being previous negative
contraception experiences and not having found a
method that suited them.
“(My) sister in law told me to use injection so I used
injection. But I had excessive bleeding. I used pills, it
also did not work. They inserted something (Implant)
but I did not like it and I haven’t used anything after
that.” PC IDI 1, Sapana, 36 years
PC respondents also reiterated fear of perceived side
effects and lack of information about contraception as a
reason for not accessing post-abortion contraception. In
contrast to PC participants, CC respondents reported in-
formation and support they received through contracep-
tive counselling during their SRH clinic appointment,
reassured them of their ability to choose a contraceptive
method that would suit them.
“They (MSC staff ) counselled me about various
methods like pills, Norplant (Implant), Copper-T
(IUD) etc. I wanted to try pills first and if it doesn't
suit me I can go for other alternatives as well… Now I
know which of the family planning methods suit me.
Otherwise I might not use contraceptives, I might
again be pregnant, and have to go for another abor-
tion.” CC IDI 4, Roghini, 32 years
Half of all respondents (CC = 4, PC = 6) shared
that their husbands did not typically reside at the family
home due to work commitments. Inconsistent contra-
ceptive use, specifically OCP, or no contraceptive use,
due to spousal separation was a recurring theme for sev-
eral participants both before and after their unwanted
pregnancies.
“I got pregnant when I was still on pills (OCP). It's
been around 5-6 years (I’ve been using pills). Whenever
my husband is here I take pills and when he goes
abroad I stop taking it… You know my husband lives
around one month here and the next three months
abroad, so I don't prefer Depo (Injectables) or Copper-
T (IUD).” CC IDI 1, Sabitri, 36 years
At the time of their interviews, of the 10 participants
whose husbands work away from the family home (ei-
ther in another part of the country or overseas), four re-
ported being on no form of contraception (CC = 1, PC =
3). Two respondents reported intermittent OCP use
(CC = 2), three were using LARCs: two had an Implant
inserted (CC = 1, PC = 1) and one participant had an
IUD (PC = 1), and one participant was not using contra-
ception as they wished to fall pregnant (PC = 1).
PC respondents reported overall limited contraceptive
use at the time of data collection in comparison to their
CC counterparts (CC = 8 and PC = 2). At the time of
their interviews, one PC respondent was not using any
contraceptive method as she wanted to conceive, and
one respondent reported current use of injectables. Of
the ten PC respondents, six reported currently not using
a modern contraceptive method, although they did not
currently wish to conceive.
Contraception and SRH information access and uptake:
general
The contrast in contraceptive and SRH information ac-
cess between the CC and PC groups at the time of
accessing MA highlights the difference in quality and
consistency of service provision. Participants from both
groups shared their experience and opinions relating to
contraception and SRH information access and uptake
outside of their immediate MA experience. Both CC and
PC participants reported various reasons for not using
contraception prior to their unwanted pregnancy, with
the majority citing previous negative experiences with
contraception use. Many participants also spoke of their
continuing concerns based on the negative contraceptive
experiences of other women.
“I heard that pills will cause injuries in uterus. I heard
that three months injection causes heavy bleeding. I
heard that Norplant (Implant) will cause cancer, so I
haven’t used any of these.” PC IDI 8, Munna, 30 years
Along with issues of reproductive coercion, the socio-
cultural pressure for Nepali women to have children was
also frequently reported by both CC and PC respon-
dents. Pressure from husbands relating to contraceptive
use was also a reported factor for both CC and PC par-
ticipants not using a modern method of contraception
prior to their unplanned pregnancy and for several re-
spondents, after their MA.
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“I told my husband that I’ll use the injection, but he
did not allow… he said that we will be cautious, so I
didn’t use (any contraception).” PC IDI 5, Sita, 25
years
Participants shared they will often base reproductive
health decision, such as the type of contraceptive
method they wish to use or where to access this method
from, on information they receive from female family
members and friends. Conversations with husbands and
family (specifically mothers, mothers-in-law, sisters and
sisters-in-law) as well as friends were reported as a
means of acquiring information on SRH. Outside of an
SRH clinic (government, I/NGO or private) or hospital
environment, participants stated other ways they receive
SRH information and SRH service provider informa-
tion included TV, radio, facebook and advertising signs
and billboards.
“(I learnt about MSC services) from TV, radio and it is
also written on signboards… Also, one of our friends
keeps on searching and sharing… (SRH) information
on Facebook which I feel very informative and useful.”
CC IDI 1, Sabitri, 36 years
However, several participants highlighted the socioeco-
nomic disparities in SRH and contraception information
access, particularly for those living in rural and remote
regions.
“We don’t have TV or radio. (Female Community
Health Volunteer) provides me information about
contraceptives, but my husband does not want me to
use.” PC IDI 4, Parvati, 30 years
Female Community Health Volunteers (FCHVs) were
the most frequently cited source of SRH information
and education as well as contraceptive access. Both CC
and PC respondents emphasised the importance of
FCHV within their communities, and how they feltsup-
ported and comfortable with them.
“I get information from health volunteers (FCHV).
They are from our community, we will be close
with them and can share.” PC IDI 7, Kalpana, 35
years
Participants also spoke of the critical role FCHVs play
in providing SRH services to women living in rural and
remote regions.
“She (FCHV) works in a health post. She asks us if we
have any problem and she travels around.” PC IDI 1,
Sapana, 36 years
Many CC and PC participants expressed an overall
lack of access to SRH information within their daily
lives, with sociocultural issues including gender discrim-
ination and SRH stigma stated as key inhibitors to SRH
information access.
Discussion
Women-centred safe abortion services support women
to holistically exercise their SRHR by providing them
with information, education and choice [40]. In contrast
to unsafe services, they address both the physical and
emotional reproductive needs of women, including
contraceptive counselling, to support women in their
MA journey [40]. Whether accessing MA through a safe
abortion service or by unsafe means, reasons informing
a woman’s decision to seek an abortion often highlight
the intersectoral nature of SRHR, cultural and gender
roles and socioeconomic status [8, 41–43].
Although the literature shows continuation of educa-
tion as a prominent factor in abortion seeking decision
making, particularly for younger women, our findings
highlight the desire to ensure access to education for the
children that women already have and is closely linked
with concerns regarding the capacity to financially pro-
vide the same for another child [8, 42]. Findings from a
2017 study across 14 countries show that while women
have abortions for a variety of reasons, the most fre-
quently cited reasons for having an abortion are socio-
economic concerns or limiting childbearing [42].
Reproductive coercion is behaviour that inhibits a
woman’s sexual and reproductive autonomy [44] and in
Nepal, like many other developing countries in Asia, is
often linked with son-preference [43–48]. Our findings
highlight the complexity reproductive coercion has on
women’s abortion seeking decision making. Research on
sex-selective abortion in Nepal remains scarce. However,
emerging evidence suggests such abortions are becoming
increasingly common and therefore must be a consider-
ation within all safe abortion and post-abortion family
planning strategies [11, 47, 49, 50].
Effective culturally-safe contraceptive counselling is an
essential component of PAC and assists women to space
births, prevent future unwanted pregnancies and avoid
unsafe abortion [22, 23]. It also plays an essential role in
ensuring women’s concerns relating to contraceptive use
are addressed, enabling women to make informed decisions
regarding which method best suits them [51]. Informed
choice increases the likelihood of post-abortion contracep-
tive use and empowerment to change methods, rather than
total contraceptive discontinuation [24, 51–53].
With access to a wide range of contraceptive methods
combined with comprehensive SRH information and edu-
cation, contraception uptake in women post-abortion has
shown to increase, however, many barriers remain [23].
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Multiple studies conducted in Nepal on post-abortion
contraception access and uptake through government, pri-
vate and NGO SRH services highlight that even at regis-
tered safe abortion services, post-abortion contraception
access and uptake remains a challenging aspect of effective
PAC provision in Nepal [51, 52, 54, 55].
Effective and safe MA provision by non-physician cli-
nicians is well documented [56–61]. Puri et al. (2018)
and Rocca et al. (2018) demonstrate in their study on
auxiliary nurse-midwife provided MA through pharma-
cies, that when pharmacy provided MA is administered
by qualified health professionals effective and safe MA
provision can be accomplished without compromising
contraceptive care [53]. With many mid-level health
providers (nurses and auxiliary nurse-midwives) proprie-
tors of pharmacies in Nepal, their study highlights an-
other promising avenue for safe and convenient MA
provision and expansion through pharmacies [53, 61].
Between 2000 and 2014, trends across Asia showed
the most frequently cited reason for women not using
contraception was infrequent or no sex, with the preva-
lence of this reason substantially increasing in Nepal,
Bangladesh and the Philippines, most likely due to in-
creasing labour migration [62]. The 2016 NDHS stated
approximately one-third of women in Nepal indicated
their spouse lives away from the family home [8]. Mul-
tiple studies from Nepal suggest spousal separation, due
to increasing male migrant workforce, is a prominent in-
fluencer of women’s uptake, continuation and/or discon-
tinuation of contraception and could potentially play a
role in Nepal’s stagnated contraceptive prevalence rate
[51, 52, 54, 55, 63–65]. To ensure the contraceptive
needs of Nepali women are met, family planning pro-
grams, SRH services and FCHVs must adjust their strat-
egies to address the SRH needs of these couples [62].
Our findings document how women seek out safe or
unsafe abortion services based on positive personal experi-
ences or from the advice of the positive experiences of
family and friends, with ease of access to services, con-
cerns regarding confidentiality and economic burden also
playing a role. Despite permissive laws and the govern-
ment’s commitment to provide free safe abortion services,
multiple Nepal based studies show awareness of the legal
status of abortion and knowledge of safe abortion services
remains low [8, 66–68]. Combined with lack of know-
ledge, barriers to access and uptake of safe abortion ser-
vices will continue to facilitate demand for MA provision
through pharmacies in Nepal [11]. It is essential SRH pol-
icymakers acknowledge the role pharmacies continue to
play in the provision of MA and establish practical strat-
egies to decrease negative health outcomes for women
and increase access and referrals to safe MA [20, 61, 69].
The SRH and contraceptive information provided to
women who seek MA through pharmacies is often
inconsistent, inaccurate or non-existent with staff at times
dispensing unsafe or ineffective forms of the drug [70, 71].
However, our study shows there is a proven desire for
some pharmacy workers to provide support and quality of
care for women seeking MA. Studies conducted in Nepal
[20, 69] and other low- and middle-income countries [70,
72–77], highlight the challenges of implementing effective
pharmacy based harm reduction strategies such as train-
ing and education of staff to help mitigate adverse health
outcomes for women. Interventions to train pharmacy
workers in harm reduction strategies in Zambia and Nepal
demonstrated improvement in knowledge and referral
practices [20, 69, 77], however, due to insufficient evidence
of safety and effectiveness, current WHO guidelines do
not recommend pharmacy staff provide MA [4].
Effective and safe MA provision by non-physician clini-
cians is well documented [56–60], with a recent Nepal based
study demonstrating MA was as effective and safe when
provided by trained auxiliary nurse-midwives at pharmacies
as at government-certified health facilities [61]. As many
mid-level health providers (nurses and auxiliary nurse-
midwives) are proprietors of pharmacies in Nepal, their
study details another promising avenue for safe and conveni-
ent MA provision and expansion through pharmacies [61].
While harm reduction strategies have the potential to
increase accurate information provision and support relat-
ing to pharmacy supplied MA [20, 69], the sale of counter-
feit brands or traditional medicines with purported
abortive ingredients in the place of authentic MA will
continue to contribute to the access of unsafe or ineffect-
ive medicine [20]. It is imperative that education regarding
authentic Nepali registered brands, authentic but unregis-
tered in Nepal brands, counterfeit MA brands and unsafe
abortive medicines be a component of any pharmacy-
based harm reduction training. Currently, there is limited
global data on the types of MA pharmacies are providing
within the WHO less safe and least safe framework [5,
78]. In Nepal, it is essential this be investigated within a
broader, and much needed, comprehensive evidence base
relating to MA provision through pharmacies to inform
effective and functional policy.
Pharmacy-based harm reduction strategies have the
potential to decrease morbidity and mortality relating to
unsafe abortion as well as increasing access to MA, par-
ticularly in remote and rural settings that lack safe abor-
tion services [11, 20, 69]. However, it is essential that
effective contraceptive counselling including information
provision, access to a range of contraceptive methods
and established SRH service referral mechanisms for
LARC insertion or permanent methods, be incorporated
into these strategies to ensure women’s post-abortion
contraceptive needs are met.
Global research has shown the effectiveness of MA self-
management and remote support through telephone
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helplines, with approximately 20 safe abortion helplines
currently active throughout Africa, Europe, Asia, and Latin
America [71, 79–83]. With nearly all households in Nepal
(93%) having access to at least one mobile telephone, re-
mote support may provide another avenue of MA support
for women and pharmacy workers [8]. Nepal based SRH
helplines such as SPN/MSN’s Meri Saathi helpline can
provide support to women and pharmacy workers with ad-
vice and information provided by trained SRH counsellors
and clinical experts [84, 85]. As well as providing accurate
SRH and MA information, trained and qualified counsel-
lors can also ensure women receive comprehensive post-
abortion contraception counselling along with referral to
health facilities for contraceptive access and post-
abortion complication support. Community-based
health care workers such as FCHVs may also benefit
from access to additional support through helpline ser-
vices, ensuring their provision of accurate SRH and safe
abortion information to women.
Our findings underscore the important role FCHVs
play in the dissemination of SRH information within the
community, with community-based health workers be-
ing the dominant community-based health asset
cited throughout the cyclical AFRPAC framework of this
study. Nepal based studies on FCHVs ability to assess
MA eligibility and determine MA success concluded fur-
ther refinement of tools are needed before effective and
widespread use could be implemented [86, 87]. However,
research shows that with effective SRHR training and
ongoing education, community based health care
workers like FCHVs can play a pivotal role in
community-based SRH information provision, contra-
ceptive counselling and access, and increasing awareness
of safe abortion services and service referral [60, 88].
While every effort was made to mitigate bias in the re-
search and to enhance credibility and trustworthiness, the
study had some limitations. Although not by design, only
married women who had already had at least one child at
the time of MA access participated in interviews. Also,
due to time constraints and access, CC participants were
only sampled from one NGO SRH service (MSC) and did
not include women who have accessed MA through gov-
ernment or private services. Recall bias due to the variable
MA access timeline for PC respondents in comparison to
CC participants is acknowledged.
Conclusion
This qualitative research is an essential contribution to
Nepal’s scarce evidence base on MA provision through
pharmacies, providing a unique and in-depth analysis of
the post-abortion experiences of women. The findings
highlight the current disparity in the post-abortion care
provision through safe abortion services and pharmacies in
Nepal. Under current Nepali legislation, MA provision
through pharmacies is considered unsafe and illegal, how-
ever through the implementation of innovative and effect-
ive harm reduction strategies, as well as access and
information expansion strategies, the potential for increased
access to safe MA throughout Nepal is evident. It is essen-
tial that post-abortion contraceptive counselling, access to a
variety of contraceptive methods, and effective referral
mechanisms to SRH services be a component of any strat-
egies addressing MA provision through pharmacies.
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